INCYTE CORP 8K

Incyte is acquiring Vega Therapeutics from Star Therapeutics for up to $2.0 billion, adding Phase 3 bleeding-disorder drug VGA039 and incurring an expected $1.25 billion R&D charge upon closing in Q3 2026.

Incyte Corporation announced that it has entered into a definitive stock purchase agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion in cash plus up to $750 million in sales-based milestone payments, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. The transaction, an equity acquisition expected to close in the third quarter of 2026 following expiration of the Hart-Scott-Rodino waiting period and satisfaction of other customary conditions, will add VGA039, a Phase 3 investigational monoclonal antibody targeting Protein S for von Willebrand disease and other bleeding disorders, to Incyte’s hematology portfolio and is expected to result in an R&D charge of approximately $1.25 billion in Incyte’s third quarter and full-year 2026 GAAP and non-GAAP results. The deal has been approved by the boards of directors of both Incyte and Star Therapeutics, and Incyte will host an analyst and investor call on June 8, 2026, to discuss the acquisition.

Filing Facts

CIK

879169

Ticker

INCY

Form

8K

Source Type

sec

Accession

0000879169-26-000040

Alert Tier

8